Other Vaccines - Tanzania

Tanzania

Highlights

In Tanzania, the revenue in the Other Vaccines market is estimated to reach US$9.73m in 2024.
It is expected to exhibit an annual growth rate of 11.23% (CAGR 2024-2029), leading to a market volume of US$16.57m by 2029.
When compared globally, United States is projected to generate the highest revenue of US$24.73bn in 2024.
Tanzania is experiencing an increased demand for other vaccines, driven by a growing awareness of the importance of immunization among the population.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Other Vaccines market in Tanzania has been developing steadily in recent years, driven by various factors such as increasing awareness of the importance of vaccination, government initiatives, and rising healthcare expenditure.

Customer preferences: Tanzanian customers have shown a growing interest in vaccines that protect against diseases not covered by routine immunization programs, such as meningitis, yellow fever, and rabies. This trend is in line with global demand for other vaccines, as people become more aware of the risks of these diseases and seek to protect themselves and their families.

Trends in the market: The Other Vaccines market in Tanzania has been growing at a steady pace, with a particular focus on meningitis and yellow fever vaccines. This is due to the high incidence of these diseases in the country, especially during the rainy season when the risk of outbreaks is highest. The government has also been actively promoting vaccination against these diseases, which has helped to increase demand. Additionally, the private sector has been investing in the development of new vaccines and expanding their distribution networks, which has further boosted market growth.

Local special circumstances: Tanzania has a large rural population with limited access to healthcare facilities, which can make it difficult to distribute vaccines effectively. To address this issue, the government has launched various initiatives to improve vaccine coverage in rural areas, such as mobile vaccination campaigns and the use of community health workers. These efforts have helped to increase access to vaccines and improve health outcomes in remote areas.

Underlying macroeconomic factors: Tanzania has experienced steady economic growth in recent years, which has led to an increase in healthcare expenditure. This has enabled the government to invest in healthcare infrastructure and expand access to vaccines. Additionally, Tanzania has a young and growing population, which presents a significant market opportunity for vaccine manufacturers. However, the country still faces challenges such as inadequate healthcare funding and a shortage of skilled healthcare workers, which can limit the growth of the Other Vaccines market in the long term.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.